,27 In particular, inactivation of ARID1A in vivo increases tumor-infiltrating lymphocytes and sensitivity to anti-PD-L1 antibody therapy in ovarian cancer, while BRCA2 mutations are enriched in melanomas responsive to ICIs.26 Here, ARID1A is linked to neoplasm.